公开(公告)号：US20230347316A1

公开(公告)日：2023-11-02

申请号：US17981262

申请日：2022-11-04

申请人： Cytiva Bioprocess R&D AB

发明人： Martin HALL ,  Sture LARSSON ,  Andreas MURANYI ,  Gustav RODRIGO ,  Jinyu ZOU ,  Per-Mikael ABERG

IPC分类号： B01J20/24 ,  B01D15/38 ,  B01J20/286 ,  C07K1/22 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K17/10

CPC分类号： B01J20/24 ,  B01D15/3809 ,  B01J20/286 ,  C07K1/22 ,  B01J20/3274 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3293 ,  C07K17/10 ,  C07K2317/55 ,  B01J2220/52 ,  B01J2220/54

摘要： The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US20210291143A1

公开(公告)日：2021-09-23

申请号：US17107600

申请日：2020-11-30

申请人： Cytiva Bioprocess R&D AB

发明人： Martin HALL ,  Sture LARSSON ,  Andreas MURANYI ,  Gustav RODRIGO ,  Jinyu ZOU ,  Per-Mikael ABERG

IPC分类号： B01J20/24 ,  B01D15/38 ,  B01J20/286 ,  C07K1/22 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K17/10

摘要： The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.